Literature DB >> 26632543

Advances in endovascular therapy to treat primary hepatocellular carcinoma.

Zhi Guo1, Haipeng Yu, Changfu Liu, Tongguo Si, Xueling Yang, Weihao Zhang, Yan Xu, Yong Li.   

Abstract

Transcatheter arterial chemoembolization (TACE) is a minimally invasive procedure to restrict a tumor's blood supply, and TACE has an established role in cancer therapy. An embolic material in the form of microspheres (such as drug-eluting beads) and transarterial radioembolization is effective at treating hepatocellular carcinoma (HCC). Endovascular therapy offers promise for the treatment of tumor thrombi in the portal vein. Many researchers are anticipating an era of TACE with microspheres. This review aims to provide an overview of advances in endovascular therapy to treat primary HCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26632543     DOI: 10.5582/ddt.2015.01057

Source DB:  PubMed          Journal:  Drug Discov Ther        ISSN: 1881-7831


  4 in total

Review 1.  Basics to advances in nanotherapy of colorectal cancer.

Authors:  Ankita Tiwari; Shivani Saraf; Ankit Jain; Pritish K Panda; Amit Verma; Sanjay K Jain
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

2.  TIPE‑2 suppresses growth and aggressiveness of hepatocellular carcinoma cells through downregulation of the phosphoinositide 3‑kinase/AKT signaling pathway.

Authors:  Lin Wang; Chen Chen; Shuzhi Feng; Jianli Tian
Journal:  Mol Med Rep       Date:  2018-03-20       Impact factor: 2.952

3.  Multiradiographic Diagnosis of Primary Hepatocellular Carcinoma and Evaluation of Its Postoperative Observation after Interventional Treatment.

Authors:  Ning Tang; Jing Zhu; Ying Zeng; Xiao Zhang; Jian Zhou
Journal:  Contrast Media Mol Imaging       Date:  2022-08-04       Impact factor: 3.009

4.  Combination therapy of hTERTR and FAM96A for hepatocellular carcinoma through enhancing apoptosis sensitivity.

Authors:  Wan-Peng Wang; Hai-Ying Gao
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.